SCHEDULE: Morgan Stanley Reduces ESSA Pharma Stake Below 5%
Beneficial Ownership Report Amendment
Morgan Stanley and its subsidiary have reported a reduction in their beneficial ownership of ESSA Pharma Inc. common shares to below the 5% threshold.
Summary
- Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley & Co. LLC, filed an Amendment No. 1 to Schedule 13G for ESSA Pharma Inc.
- The filing indicates that Morgan Stanley has ceased to be the beneficial owner of more than five percent of ESSA Pharma Inc.'s common shares.
- As of the event date of September 30, 2025, Morgan Stanley beneficially owned an aggregate of 1,904,062 common shares, representing 4.0% of the class.
- Morgan Stanley & Co. LLC reported 0.0% beneficial ownership of ESSA Pharma Inc. common shares.
Sentiment
Score: 5
Explanation: Neutral. The filing is a routine disclosure of a change in institutional ownership, not directly indicative of positive or negative company performance or operational status.
Stakeholder Impact
- Shareholders: May interpret the reduction in a significant institutional investor's stake as a change in investment conviction or portfolio strategy, potentially influencing market sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement |
| 10/07/2025 | Signature date of the Schedule 13G Amendment No. 1 filing |
Keywords
ESSA Pharma, Morgan Stanley, Schedule 13G, beneficial ownership, common shares, institutional investor, stake reduction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.